title: Activating types 1 and 2 angiotensin II receptors modulate the hypertrophic differentiation of chondrocytes.
abstract: A local tissue-specific renin-angiotensin system (local RAS) has been identified in many organs. However, no report has described the role of a local RAS in the hypertrophic differentiation of chondrocytes. To examine the role of a local RAS in the hypertrophic differentiation, we activated angiotensin II type 1 receptor (AT1R) and angiotensin II type 2 receptor (AT2R) separately in the cell line ATDC5, which involves differentiation from mesenchymal stem cells to hypertrophic chondrocytes. Activation of AT1R suppressed and activation of AT2R enhanced the expression of markers of hypertrophic differentiation, including type X collagen, matrix metalloproteinase 13 and runt-related transcription factor 2.
authors.affiliation: Department of Orthopaedic Surgery, Faculty of Medicine, Kinki University, 377-2 Ohno-Higashi, Osaka-Sayama City, Osaka 589-8511, Japan.
authors.forename: Ichiro
authors.initials: I
authors.lastname: Tsukamoto
authors.forename: Shinji
authors.initials: S
authors.lastname: Inoue
authors.forename: Takeshi
authors.initials: T
authors.lastname: Teramura
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Takehara
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Ohtani
authors.forename: Masao
authors.initials: M
authors.lastname: Akagi
keywords: ATDC5; Angiotensin II type 1 receptor; Angiotensin II type 2 receptor; Hypertrophic differentiation; Local RAS
references.citation: Exp Clin Endocrinol. 1994;102(3):252-61
references.pmid: 7995347
references.citation: Biochem Biophys Res Commun. 2013 May 10;434(3):647-52
references.pmid: 23583236
references.citation: Arthritis Rheum. 2007 Feb;56(2):441-7
references.pmid: 17265479
references.citation: Nat Cell Biol. 2004 Jun;6(6):499-506
references.pmid: 15146194
references.citation: J Assist Reprod Genet. 1994 Mar;11(3):117-22
references.pmid: 7827440
references.citation: J Cell Physiol. 2007 May;211(2):392-8
references.pmid: 17167786
references.citation: J Hypertens. 2006 Mar;24(3):581-9
references.pmid: 16467662
references.citation: Br J Pharmacol. 2009 Nov;158 Suppl 1:S1-254
references.pmid: 19883461
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2002 Nov;366(5):381-416
references.pmid: 12382069
references.citation: Peptides. 2005 Aug;26(8):1401-9
references.pmid: 16042980
references.citation: FASEB J. 2008 Jul;22(7):2465-75
references.pmid: 18256306
references.citation: Curr Opin Pharmacol. 2011 Apr;11(2):187-92
references.pmid: 21167778
references.citation: Biochemistry. 1998 Nov 10;37(45):15791-8
references.pmid: 9843384
references.citation: Br J Pharmacol. 2010 Apr;159(8):1672-80
references.pmid: 20233225
references.citation: J Endocrinol. 1998 Mar;156(3):543-50
references.pmid: 9582511
references.citation: Hypertension. 1979 Jul-Aug;1(4):384-8
references.pmid: 396241
references.citation: Eur J Pharmacol. 1995 Oct 16;285(2):181-8
references.pmid: 8566137
references.citation: J Biol Chem. 2006 Jul 14;281(28):19288-95
references.pmid: 16690611
references.citation: Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10663-7
references.pmid: 7479861
references.citation: Physiol Rev. 2006 Jul;86(3):747-803
references.pmid: 16816138
references.citation: J Biol Chem. 2001 Oct 26;276(43):39721-6
references.pmid: 11507095